News

PolyPid to Showcase Q1 Financial Results and Innovations

PolyPid to Showcase Q1 Financial Results and Innovations

PolyPid's Upcoming Financial Report

Petach Tikva, Israel - PolyPid Ltd. (NASDAQ: PYPD), a forward-thinking biopharmaceutical company dedicated to enhancing surgical outcomes, is preparing to announce its financial results for the first quarter of 2025. This all-important report will be released just before U.S. financial markets open on a Wednesday in mid-May. Following this release, PolyPid will host a conference call and a live webcast at 8:30 AM Eastern Time to discuss the details of its financials and provide an update on its ongoing operations.

Conference Call Details

For shareholders and interested parties wishing to participate, it’s recommended to register at least five minutes prior to the call. If you’re not planning to ask questions, you might find it more convenient to listen via the webcast instead. This format allows for broader access and engagement with the company’s updates.

About PolyPid Ltd.

Founded as a late-stage biopharmaceutical company, PolyPid Ltd. aims to make significant strides in the surgical field. Their innovative approach employs local administration of prolonged-release therapeutics through the proprietary PLEX technology. This advanced system allows for optimal drug delivery tailored to surgical needs, with controlled release over varying durations—spanning from a few days to several months.

Currently, PolyPid is spearheading its lead product candidate, D-PLEX100, which is in a critical Phase 3 clinical trial aimed at preventing infections in abdominal colorectal surgeries. Beyond this, PolyPid is also venturing into new territories with its OncoPLEX initiatives, focusing on solid tumors such as glioblastoma, which are in preclinical evaluation stages.

Company Contacts

For further inquiries and detailed information, the company's investors and those interested in more comprehensive queries can reach out via email. Ori Warshavsky, the Chief Operating Officer for the U.S., is readily available at 908-858-5995 or through the email address IR@Polypid.com. Investors can also connect with Brian Ritchie from LifeSci Advisors for related concerns at 212-915-2578 or at Britchie@lifesciadvisors.com.

Frequent FAQs

What are PolyPid's key product innovations?

PolyPid is focusing primarily on its D-PLEX100, aimed at preventing surgical infections, and OncoPLEX, targeting solid tumors like glioblastoma.

When will the Q1 results be released?

The financial results for the first quarter of 2025 will be announced on a Wednesday in mid-May, before the U.S. markets open.

How can investors access the conference call?

Investors can register for the conference call at least five minutes before the start time to participate or listen to the live webcast.

What is PolyPid's mission?

PolyPid aims to improve surgical outcomes through innovative drug delivery technologies, reducing risks associated with surgical procedures.

Where can I find more information about PolyPid?

Further details can be found on PolyPid's official website or through their social media channels on Twitter and LinkedIn.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Samuel Oschin Center Opens, Promising Wonder

Updated Category News Views 179

A Grand New Space for Space Well, here's a sight for sore eyes—California Science Center's Samuel Oschin Air and Space Center just swung its doors open wide, and boy, it's a beast of a place. Housing a spectacle like the Space Shuttle Endeavour in a vertical launch position, it's as if they've reached up and snagged a piece of the sky itself for their exhibits. They're...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 106

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 137

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 74

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 106

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
MV Transportation Celebrates Leadership Nomination for FTA

Updated Category News Views 150

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 95

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
IM Cannabis's Third Quarter Financial Jolt

Updated Category News Views 143

IM Cannabis Takes a Hit, But Seeks New Angles Diving into IM Cannabis's (NASDAQ: IMCC) latest financial splash is like reading a weathered old map of the stock market. The third quarter of 2026 wasn't kind to this little cannabis outfit. Revenues have nosedived to C$1.65 million from last year's C$5.08 million. It's not just the typical bad quarter blues; it's a solid...

Continue Reading

Top 5 Most Recently Viewed Articles

Berry Global Plans Senior Secured Notes Offering Ahead of Merger

Updated Category News Views 126

Berry Global’s Strategic Offering of Senior Secured Notes In an exciting development, Berry Global Group, Inc. (NYSE:BERY) has outlined plans for the issuance of senior secured notes through its subsidiary, Treasure Escrow Corporation. This move is a crucial step in conjunction with the anticipated merger of Berry's Health, Hygiene and Specialties Global Nonwovens and...

Continue Reading
Hexaware Technologies Expands Presence with New London HQ

Updated Category News Views 260

Hexaware Technologies Expands Its Footprint with New Headquarters Hexaware Technologies, a renowned name in the realm of IT, AI, and digital services, has recently taken a significant step by inaugurating its new UK headquarters at One Canada Square, in the vibrant Canary Wharf area. This new facility is set to play a crucial role in the company’s strategy to enhance...

Continue Reading
Aroa Biosurgery Advances in Treating Venous Leg Ulcers

Updated Category News Views 343

Aroa Biosurgery Advances in Treating Venous Leg Ulcers Aroa Biosurgery, a leading name in soft tissue regeneration technology, has achieved a significant milestone in clinical evidence for their proprietary Endoform product. The company announced that over 100 peer-reviewed studies now confirm the efficacy of their AROA ECM technology in treating various wound types....

Continue Reading
Innovative Paver Spacer Designed for Perfect Alignment

Updated Category News Views 231

Revolutionizing Landscape Design with a New Paver Spacer The landscape industry is continuously evolving, and one of the most exciting innovations to recently emerge is a specialized paver spacer. This unique design addresses a common problem faced by landscapers and homeowners alike: the challenge of aligning concrete or clay pavers effectively. An inventor with a vision...

Continue Reading
Transforming Diagnostics: The Rise of Digital Pathology Market

Updated Category News Views 232

Understanding Digital Pathology Market Dynamics In recent years, the Digital Pathology Market has emerged as a key player in the healthcare sector, showing significant growth and innovation. With an expected market size of USD 2.92 billion by the end of the forecast period, the sector has captured investor interest and demonstrated the potential to reshape diagnostic...

Continue Reading